| Mr Matthew Zaino, DPT | |
|
2 Computer Dr W, Ste 200, Albany, NY 12205-1622 | |
| (518) 489-2524 | |
| (518) 489-3167 |
| Full Name | Mr Matthew Zaino |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 6 Years |
| Location | 2 Computer Dr W, Albany, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285112417 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Secondary |
| 225100000X | Physical Therapist | 043855 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nje Pt Movement Pllc | 9739408295 | 13 |
News Archive
A University of Cambridge study, which set out to investigate DNA methylation in the human heart and the 'missing link' between our lifestyle and our health, has now mapped the link in detail across the entire human genome.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.
Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
› Verified 2 days ago
| Provider Name | John W Repsher Pt Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1922024298 PECOS PAC ID: 2860414349 Enrollment ID: O20051227000559 |
News Archive
A University of Cambridge study, which set out to investigate DNA methylation in the human heart and the 'missing link' between our lifestyle and our health, has now mapped the link in detail across the entire human genome.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.
Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
› Verified 2 days ago
| Provider Name | Nje Pt Movement Pllc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1750775995 PECOS PAC ID: 9739408295 Enrollment ID: O20150811004375 |
News Archive
A University of Cambridge study, which set out to investigate DNA methylation in the human heart and the 'missing link' between our lifestyle and our health, has now mapped the link in detail across the entire human genome.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.
Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Matthew Zaino, DPT 2 Computer Dr W, Ste 200, Albany, NY 12205-1622 Ph: (518) 489-2524 | Mr Matthew Zaino, DPT 2 Computer Dr W, Ste 200, Albany, NY 12205-1622 Ph: (518) 489-2524 |
News Archive
A University of Cambridge study, which set out to investigate DNA methylation in the human heart and the 'missing link' between our lifestyle and our health, has now mapped the link in detail across the entire human genome.
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.
Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.
The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
› Verified 2 days ago
Jordan Iris Bakowski, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 900 Watervliet Shaker Rd, Suite 102, Albany, NY 12205 Phone: 518-862-4900 | |
Yuan Kenneth Jin, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 121 Everett Rd Ste 200, Albany, NY 12205 Phone: 518-489-2524 Fax: 518-489-3167 | |
Penelope M Blasch, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 314 S Manning Blvd, Albany, NY 12208 Phone: 518-453-2273 | |
Heather M. Lacasse, MPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 121 Everett Rd Health Park, Albany, NY 12205 Phone: 518-489-2524 Fax: 518-489-3167 | |
Marianna Vaysman, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 281 Sand Creek Rd, Albany, NY 12205 Phone: 518-459-1292 Fax: 518-459-1296 | |
Kimberly Silvernail Keane, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 314 S Manning Blvd, Albany, NY 12208 Phone: 518-453-2273 | |
Dr. Janel Lena Carver, D.P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 80 Clinton Ave Apt 1, Albany, NY 12210 Phone: 914-299-9514 |